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Polymerase inhibitorsThe development of antiviral strategies to prevent or treat respiratory syncytial virus (RSV) infections is
of great importance, especially considering the fact that RSV is one of the most important causes of pedi-
atric respiratory infections. However, despite intense efforts, there is no antiviral or vaccine approved for
the prevention or treatment of RSV infections. Several inhibitors, targeting different RSV proteins have
been discovered over the past decade. We here review the most important chemical series as well as
recent developments in understanding which viral proteins and/or host cell factors are good targets
for inhibition of viral replication. In addition, we highlight the current in vitro and in vivo model systems
of the disease. A number of molecules are currently in (advanced) preclinical or clinical development.
Significant breakthroughs in the field may be expected in the upcoming years.
 2016 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. RSV burden of disease, epidemiology and transmission
The respiratory syncytial virus (RSV) is a pneumovirus that
belongs to the family of the Paramyxoviridae. The virus infects vir-
tually all children by the age of three, making it the most important
viral agent causing severe respiratory illness in infants and chil-
dren worldwide. More specifically, RSV infections are responsible
for one-third of acute lower respiratory infection related deaths
in infants less than one year of age and are particularly problematic
in premature babies as well as in children with underlying cardiac
and respiratory problems [1]. The virus causes also significant dis-
ease in elderly [2,3] as well as in transplant recipients.
RSV is transmitted by contact with oral or nasal secretions,
causing repeated infections throughout life. An RSV infection elicits
both innate and adaptive immune responses, however immunity
against the virus is not long-lived. The fusion (F) and attachment
(G) surface glycoproteins have the ability to induce neutralizing
antibodies, which wane quickly after infection [4]. RSV shows sea-
sonal circulation in more temperate climate regions, with highest
detection rates in late fall and early spring, in contrast to tropical
regions were RSV is detectable year round, although the latter is
not a consistent finding [5,6].Currently, infected patients mainly receive symptomatic treat-
ment consisting of bronchodilators and mucolytic agents, while
high-risk young pediatric patients (<29 weeks gestation without
chronic lung disease) also receive prophylactic treatment with
monoclonal antibodies (Palivizumab) [7]. The observation that a
higher viral load on day three of hospitalization was associated
with a requirement for intensive care and respiratory failure in
children under two years of age indicates there is a potential ther-
apeutic window for the use of antivirals in this patient population
[8]. Ribavirin is currently the only small molecule that has been
approved for treatment of serious RSV infections, but its use is lim-
ited because of side effects, lack of efficacy, difficult route of
administration and high cost.2. Genetic diversity and genome organization
RSV is an enveloped, non-segmented, single stranded negative
sense RNA virus with a genome size of approximately 15.2 kb. The
ten genes encode for eleven proteins named NS1, NS2, N, P, M, SH,
G, F, M2-1, M2-2 and L. RSV can be divided into two subgroups
RSV-A and RSV-B, which contain different genotypes based on the
nucleotide sequence of the carboxy-terminal ectodomain of the G
protein [9]. A genotype classification system based on a gene seg-
ment of 629 bp for RSV-A and 724–762 bp for RSV-B, comprising
both the conserved region and the hypervariable regions of the G
protein has been developed [10,11]. Currently, for RSV-A theochem.
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13 genotypes (GB1 to GB13) have been distinguished for RSV-B [12].
Evolutionary rates were determined for both RSV-A and RSV-B,
showing a much higher substitution rate for the attachment of G
protein (1.83  103 and 1.95  103 substitutions/site/year for
RSV-A and RSV-B respectively), compared to the genomic evolu-
tionary rate based on the complete genome (6.47  104 and
7.76  104 substitutions/site/year for RSV-A and RSV-B respec-
tively) [10,13,14].3. In vitro and in vivo model systems
3.1. Cell lines and human airway epithelial cells
In vitro, RSV replicates most efficiently in immortalized cell lines
of human epithelial origin, although the virus also replicates in a
rather wide range of cell lines, derived from various tissues and
hosts. RSV tends to remain cell associated, making it necessary to
dislodge the virus from the cells by freeze-thawing, sonication, or
vortexing, in order to generate high titer virus stocks. Themost com-
monly used cell line to grow RSV is the humanHEp-2 cell line. How-
ever, thepurityof this cell linehasnotbeen fully established,making
it less suited for the production of virus for in vivo applications [15].
Vero cells are also known to be susceptible to grow RSV, although it
has been reported that the progeny virus contains a truncated
attachment protein that reduces its infectivity and the loss of virus
G-protein binding to cell surface glycosaminoglycans [16].
Cell lines have several limitations, such as their cancerous origin,
non-respiratory origin and often also inability to grow clinical viral
isolates. These problems can be overcome by the use of isolated air-
way epithelial cells grown at an air-liquid interface. This results in
the generation of a pseudostratified, mucociliary airway epithelium
that displays similar morphologic and phenotypic characteristics of
the in vivo human cartilaginous airway epithelium [17]. Studies in
this humanairway epithelium (HAE) have shown that RSVpreferen-
tially infects ciliated cells located at the apical surface and uses
CX3CR1 as a receptor [18,19]. This technique has been successfully
used to adapt clinical RSV isolates to cell culture [20].3.2. In vivo models using surrogate viruses and non-human primate
models
Large animal models of RSV include non-human primates,
calves and lamb and their use has been reviewed recently
[21,22]. Briefly, infection of calves with bovine RSV results in sev-
ere disease with a pathology and immunological response that is
comparable to that of human RSV infections in children [23].
Bovine RSV infection in cattle is responsible for significant eco-
nomic losses to the farming industry. Intranasal infection of lamb
with human RSV results in moderate clinical signs of both the
upper and lower respiratory tract. In particular Memphis 37, a clin-
ical strain of human RSV, has been used to infect neonatal lamb
and causes a disease that is comparable to that of RSV infections
of human infants [24]. Infection of chimpanzee with the human
RSV results in only mild disease that is limited to the upper respi-
ratory tract [25]. The bovine, ovine and non-human primate mod-
els have advantages of sample collection, anatomical similarity of
the respiratory track (non-human primates, sheep) and reliable
pulmonary function measurements, but they also have obvious
disadvantages. For example, bovine- and ovine RSV are genetically
different from human RSV, the use of these animals poses housing
and husbandry issues, limited molecular tools are available for
these animals and large quantities of inhibitors are needed for such
studies. Altogether these disadvantages highlight the need for
robust and convenient small animal RSV infection models.Please cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.0143.3. Small animal models using human RSV
Cotton rats are semi-permissive for human RSV infection with
both upper and lower respiratory tract infection [26,27]. Peak pul-
monary replication is observed on day 4 post infection with virus
clearing from the lungs by day 7 post infection (or earlier). Cotton
rats have been widely used for modeling respiratory viral infec-
tions and the peak RSV levels are 100 x higher than in mice.
Lower respiratory tract infection is already achieved in this model
upon intranasal infection with 104 plaque-forming-units (PFU)
whereas >105 PFU is needed in mice. For this reason, the cotton
rat model has been the preferred animal model for studying RSV
replication and testing antivirals. The pathology associated with
RSV challenge in cotton rats consists of only mild to moderate
bronchiolitis or pneumonia. The model was used intensively to
study how a formalin-inactivated RSV vaccine candidate caused
enhanced respiratory disease following natural RSV infection.
However recent results highlight that also non-viral products from
the vaccine and challenge preparations give rise to enhanced dis-
ease, which limits the validity of this model [28]. The cotton rat
model has also been modified, using a high-dose cyclophos-
phamide as immunosuppressive therapy, to replicate the persis-
tent RSV pneumonia seen in stem cell transplant recipients. In
this model RSV replication remains high for at least 16 consecutive
days allowing the study of therapeutic interventions [29].
Also inbred laboratory mouse strains have been explored inten-
sely as a model for RSV infection [21]. Compared to the cotton rat
model a very high intranasal inoculum (105 to 107 PFU per mouse)
is often administered, in order to have some signs of lower respira-
tory tract infection, while the peak levels on day 4 post infection in
the lungs are rather low (104 PFU/g tissue). As in the cotton rat
model the virus is eliminated by day 7 post infection. Several
attempts have been made to improve the model by immunosup-
pression. A 5-day cyclophosphamide pretreatment of BALB/C mice
resulted only in a moderate increase in virus titers (2x) and virus-
induced pathology [30]. The use of nude mice, which are athymic
BALB/c mice that cannot generate mature T-lymphocytes, turned
out to be more successful [31]. Infection of these animals results
in peak levels that are 100 fold higher than those in BALB/c mice
and the virus remains detectable for at least 9 days after infection.
Also more severe inflammation of the airways was observed in the
nude mice compared to immunocompetent BALB/c mice.
More recently the effect of infection with several RSV strains,
including low-passage clinical isolates, was explored in the BALB/c
micemodel [32]. This revealed that infectionwithoneparticular iso-
late (strain 2–20) was associated with more significant lung dys-
function, as measured by increased breathing effort, airway
resistance and mucin expression. Interestingly the viral load in the
lungs of mice infected with these isolates was comparable or even
lower compared to mice infected with the laboratory strain A2.
Another RSV strain (Line 19) results in an increased mucus produc-
tion and pathogenicity compared to the infection with strain A2.
Line 19 is an older RSV strain that has been intensively passaged in
laboratory cell lines. The virulence of Line 19was linked to the F pro-
tein through the studies of chimeric strains andmore recentlymuta-
tions in this protein have been explored for their role in disease
pathology [33]. This shows that increased fusogenicity of the F pro-
tein of strain Line 19 correlates with many aspects of the pathology
but not with the induced high levels of airway mucin expression.
Immunocompromised ferrets are also a potential model to
study human RSV replication. In a recent study an intratracheal
inoculation (105 PFU/animal) of a low passage RSV A clinical isolate
in immunocompromised ferrets showed significant levels of repli-
cation (105–106 copies/mL peak levels) for >10 days. In the same
experiments delay of virus peak levels could be observed when
animals were pretreated with Palivizumab indicating the potentiall systems in respiratory syncytial virus antiviral drug discovery, Biochem.
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handled allowing day-to-day collection of clinical specimens
(throat and nose swaps). In addition, the authors of the study spec-
ulate on their potential use as an RSV transmission model as high
levels of RSV replication are observed in the tracheal epithelial
cells. The model also has its challenges as significant variability
in virus titer was observed between the different animals which
is not unexpected as ferrets are outbred non-SPF animals [34].4. Drug candidates for treating RSV infections
4.1. Entry as target
4.1.1. Antibodies
Palivizumab (Synagis) is a humanized monoclonal antibody
that interacts with a conserved epitope located in the antigenic site
II of the F protein. Prophylactic administration of this antibody is
advised in high-risk young infants but it requires repeated injec-
tions, is very expensive and only effective in a prophylactic con-
text. The eligibility criteria for Palivizumab administration
changed in 2014, removing the routine Palivizumab administration
for children born between 29 and 35 weeks gestation without
chronic lung disease and discontinuing prophylaxis in any child
after RSV infection, resulting in significant less use (a reduction
of 11.4 doses per 1000 children <24 months) [35]. AstraZeneca
developed an affinity matured humanized monoclonal antibody –
denominated Motavizumab (MEDI-524/Numax), that differs in
13 amino acids from Palivizumab; it has a greater affinity and
increased in vitro potency [36]. Despite promising results in mice,
the development was discontinued when treatment of infants hos-
pitalized with respiratory syncytial virus infection did not decrease
viral load or severity of illness [37,38]. Other companies develop-
ing anti-RSV antibodies include Ablynx and Regeneron. Ablynx
completed phase 1 studies (NCT01483911 and NCT01875926) for
its nanobody administered via pulmonary inhalation, while Regen-
eron is more advanced in the development of a fully human mon-
oclonal antibody (REGN2222) that also targets the F protein and is
intramuscularly administered. Its efficacy and safety, for the pre-
vention of medically attended RSV infection in preterm infants is
being evaluated during a phase 3, randomized, double-blind,
placebo-controlled study (NCT02325791). The estimated primary
completion date of the study is July 2016 [39].4.1.2. Fusion inhibitors
The entry of RSV into host cells involves two membrane pro-
teins, a trimeric fusion (F) glycoprotein, and an attachment (G) gly-
coprotein. More specifically, cell entry is mediated by the class I
viral F protein in response to binding of a host receptor by the
attachment protein. During posttranslational processing, the
fusion peptide of F is released and, upon receptor-induced trigger-
ing, inserts into the host cell membrane. As F undergoes a dramatic
refolding from its metastable pre-fusion to the stable 6-helix bun-
dle (6HB) post-fusion conformation, the host and viral membranes
are brought together, allowing fusion and entry of the viral ribonu-
cleoprotein complex [40,41]. The RSV G-protein is not essential for
viral entry, in contrast to the attachment proteins of other
paramyxovirinae, although it does contribute to the efficiency of
entry [16,42]. Thus far, one compound targeting the G-protein of
RSV has been described (MBX-300, Microbiotix, previously called
NMSO3). It is thought to inhibit attachment by blocking electro-
static binding between the viral envelope and cell membrane
[43]. Safety and efficacy of this sulfated sialyl lipid compound were
already demonstrated in animal models. In contrast to the G-
protein, the F-protein is critical for entry and is the main target
for antivirals currently under development (Fig. 1).Please cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.0144.1.2.1. Compounds with a putative same mode of fusion inhibition:
GS-5806, MDT-637 (VP-14637); JNJ-2408068 (R-170591);
TMC353121; BMS-433771; BTA-C585; P13 and C15. Initially, a study
by Douglas and colleagues revealed that MDT-637 (VP-14637) and
JNJ-2408068 (R-170591) inhibit RSV fusion by a similar mecha-
nism [44]. In vitro, drug-resistant selected variants exhibit signifi-
cant cross-resistance to both inhibitors and carry various single
amino acid substitutions in two distinct regions of the viral F pro-
tein, the heptad repeat 2 (HR2; mutations D486N, E487D, and
F488Y), and the intervening domain between HR1 and HR2 (muta-
tion K399I and T400A) (Fig. 2A). These different ‘‘escape hotspots”
were shown to be located in close proximity to each other in the
pre-fusion confirmation [45]. Altogether, different studies have
indicated that VP-14637 and JNJ-2408068, as well as GS-5806,
BMS-433771, P13, C15 and BTA-C585, interfere with RSV fusion
through a mechanism involving a similar interaction with the F
protein. Studies have shown that the central amino acid in the
middle alpha helix of the pre-HRA domain, Y198, is a critical bind-
ing site for these compounds and an essential amino acid for the
correct functioning of the F protein [46,47]. More recently, in addi-
tion to this direct mechanism of escape, indirect escape has been
suggested, were destabilizing mutations in RSV F protein lower
the barrier for prefusion F triggering, resulting in a decreased win-
dow of opportunity for the inhibitors to bind [45]. However, Battles
and colleagues reported that this decreased stability and enhanced
fusogenicity are not general properties of resistant viral strains
[46].
4.1.2.1.1. GS-5806. GS-5806 (Presatovir, Gilead Sciences) is an
allosteric inhibitor of the F-protein that blocks viral entry. It is
the first of the orally available drug candidates for which a phase
2 clinical trial has been completed. GS-5806 was found to be active
in vitro to a wide range of RSV clinical isolates [48]. In this study
RSV strains resistant to GS-5806 that were generated in vitro were
shown to carry mutations L138F and F140L/N571I in the F protein
for RSV-A and F488L or F488S for RSV-B (Fig. 2A). In a phase 2a trial
(NCT01756482) study participants (healthy volunteers experimen-
tally infected with RSV) were divided in seven cohorts and the
compound was first administered within 5 days after infection
(but before the onset of symptoms). Cohorts 1–4 received a first
dose of 50 mg of GS-5806 and then 25 mg daily for the next 4 days,
cohort 5 received a first dose of 50 mg and then 25 mg daily for the
next 2 days, cohort 6 received one 100-mg dose, and cohort 7
received a first dose of 10 mg and then 5 mg daily for the next
4 days. GS-5806 treatment reduced viral load in nasal washes
(adjusted mean, 250.7 vs. 757.7 log10 plaque-forming-unit equiva-
lents [PFUe]  hours per milliliter; P < 0.001) and severity of symp-
toms of the RSV infection (lower area under the curve for the
change from baseline in symptom scores (adjusted mean, 20.2
vs. 204.9  h; P = 0.005)). Such beneficial effect had never before
been demonstrated with other small molecule RSV inhibitors
[49]. The adult subjects enrolled in this phase 2a study showed
treatment-emergent GS-5806 resistant RSV variants in which the
F140L and T400I mutations were most frequently observed
(Fig. 2A) [50]. The fact that a mutation in the hotspot around F-
residue 400 (D401E) has shown to remain its pathogenicity in a
mouse model raised concerns that mutations in this hotspot could
become prevalent in circulating RSV strains if this compound
would be used in the clinic [45]. Gilead is currently recruiting for
placebo-controlled phase 2 studies to study the safety and efficacy
of GS-5806 in patients that have been naturally infected with RSV
and who have been hospitalized with acute respiratory symptoms
(NCT02135614). The efficacy and safety will also be studied in high
risk patients such as lung transplant recipients with RSV infection
(NCT02534350) and in hematopoietic cell transplant recipients
that suffer from infections of the upper and lower respiratory tract
(NCT02254408 and NCT02254421 respectively).l systems in respiratory syncytial virus antiviral drug discovery, Biochem.
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Fig. 1. Structural formulae of molecules inhibiting the respiratory syncytial virus fusion process.
4 E. Heylen et al. / Biochemical Pharmacology xxx (2016) xxx–xxx4.1.2.1.2. MDT-637. VP-14637 (ViroPharma/Gilead) is a reformula-
tion of MDT-637 for improved aerosol delivery. VP-14637 demon-
strates antiviral activity against RSV-A strain A2, with an EC50
value of 1.4 nM. It binds directly to the F protein and interferes
with fusion of the virus with the host cell (EC50 of 5.4 nM observed
in RSV-mediated cell fusion assay). The interaction with F involves
both heptad repeat domains of the protein trimer [51]. The com-
pound also has in vitro antiviral activity (EC50 1.72 nM) against
75 RSV clinical isolates (both RSV-A and RSV-B) [48]. During this
study in vitro resistance mutations in de F-gene were selected
using strains RSV A2 (F488I or T400I/N517I) and RSV-B 18537
(L141V) (Fig. 2A). In vivo tests in cotton rats using divided-dose
aerosol of only 126 lg drug/kg and starting on day 1 after RSV-A
or RSV-B challenge resulted in significantly lower mean pulmonary
RSV titers and reduced histopathology scores as compared to
mock- or vehicle-treated animals [52]. Preclinical studies revealed
that the compound could be delivered in both the upper and lower
respiratory tract [53]. Phase 1 study data were presented in
abstract form in 2012 [54]. A Phase IIa trial of VP-14637 (EudraCT
Number: 2012-001107-20) in 2012 in healthy subjects challenged
with RSV was initiated but was halted for unknown reasons.
4.1.2.1.3. JNJ-2408068. A benzimidazole derivative, JNJ-2408068
(R-170591), was reported with an EC50 of 0.16 nM against RSV-APlease cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.014Long strain, which is roughly 100,000 fold more potent that the
activity of ribavirin (15 lM) [55]. Antiviral activity was confirmed
for subgroup A and B clinical isolates of human RSV and for a
bovine RSV isolate. The compound did not inhibit the growth of
representative viruses from other Paramyxovirus genera. One
resistant virus isolate was raised showing single point mutations
in the F-gene (D486N) (Fig. 2A). JNJ-2408068 also inhibit the
release of proinflammatory cytokines IL-6, IL-8 and Rantes from
RSV-infected A549 cells. This compound has long tissue retention
times in several species (rat, dog, and monkey), because of its ami-
noethylpiperidine moiety, which created concern and halted fur-
ther development [56,57].
4.1.2.1.4. TMC353121. The morpholinopropylaminobenzimidazole
TMC353121 (Johnson & Johnson) is an optimized derivative of
JNJ-2408068 that lacks the long tissue retention of its predecessor
[55,57–59]. It prevents virus-cell as well as cell-cell fusion in vitro.
TMC353121 inhibits fusion by disturbing the 6HB post-fusion for-
mation [60] which is formed by intramolecular interactions of
trimeric-coiled coil HR1 with 3 anti-parallel oriented HR2 [61].
HR1 and HR2 associate with each other trough a hydrophobic cav-
ity which is considered to be the potential drug-binding site
[62,63]. TMC353121 was shown to directly interact with both
HR1 and HR2, stabilizing their interaction in a different 6HBl systems in respiratory syncytial virus antiviral drug discovery, Biochem.
Fig. 2. Schematic overview of the domains of the F- and L-proteins of RSV, the most relevant inhibitors of these proteins and the positions of resistance associated mutations
(RAMS). Numbers above the proteins indicate the amino acid positions of the RAMs. Dots below the proteins indicated the amino acid positions where the RAMs for the
different inhibitors have been described. The name of the different inhibitors are indicated on the left. (A) The RSV F-protein contains 9 domains: The hydrophobic signal
peptide (SP), the F2 and F1 subunit domains, the 27 amino acid peptide (p27) which is released from the hRSV-F molecule after complete cleavage, the fusion peptide (FP), the
heptad repeat (HR) sequences of the F1 chain, the transmembrane anchor (TM) and the cytoplasmic tail (CT) (B) The RSV L-protein contains 5 domains: the RNA dependent
RNA polymerase (RdRP), the capping domain with GDP-polyribonucleotidyltransferase activity (CAP), then connection domain (CD), the methyltransferase (MT) and the C-
terminal domain (CTD). References can be found in the text.
E. Heylen et al. / Biochemical Pharmacology xxx (2016) xxx–xxx 5conformation than its natural one. More and more data indicate
another potential mechanism of action which involves antagoniz-
ing fusion by preventing triggering of the metastable pre-fusion
confirmation of the F-protein [46]. TMC353121 has also been stud-
ied in in vivo models, including mouse [64], rat [65] and non-
human primates [59]. In BALB/c mice that had been infected intra-
nasally with RSV A2 and treated with TMC353121 (at dose ranging
from 0.25 to 10 mg/kg) viral load in the lung was reduced if treat-
ment was initiated within two days of infection. Efficacy testing of
TMC353121 in the RSV cotton rat and African Green Monkeys
models revealed a reduction in viral load in a dose-dependent
manner.
4.1.2.1.5. BMS-433771. BMS-433771 is a small molecule RSV inhi-
bitor with an average in vitro EC50 of 20 nM against RSV-A and RSV-
B laboratory strains and clinical isolates [66,67]. BMS-433771-
resistant viruses were found to carry single amino acid mutations
(F140I, V144A, D392G, K394R, D489Y) in the F1 domain of F-
protein (Fig. 2A). The compound was also shown to be efficacious
in two rodent RSV infection models (BALB/c mice and cotton rat
models) when dosed orally prior to infection, suggesting it might
be usefully prophylactically but not therapeutically [68]. Direct
affinity labeling studies indicate that the compound binds the
hydrophobic cavity where HR1 and HR2 associate to form a six
helical coiled-coil bundle (or trimer-of-hairpins), and presumably
interferes with the functional association of these heptad repeats
[67,69]. However, as for other RSV entry inhibitors, another mech-
anism of action, such as blocking the prefusion RSV F trimer has
been suggested for BMS-433771 [45].
4.1.2.1.6. BTA-C585. BTA-C585 (Biota/Aviragen) inhibits in vitro
replication of RSV-A and B (including clinical isolates) with EC50
values below 100 nM. The compound was demonstrated to target
the F protein, as drug-resistant variants that had been selectedPlease cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.014in vitro were shown to carry mutations S404C and F488L in this
protein. This is in line with the fact that the compound is cross-
resistant with other fusion inhibitors such as MDT-637 and BMS-
433771 (Fig. 2A). Activity could be demonstrated in the RSV cotton
rat model, where BTA-C585 was orally dosed at 25, 50, 100,
250 mg/kg two hours prior to infection with 104 pfu/mL of RSV-A
strain Long, showing a 1.0–3.0 log10 reduction in the viral mRNA
detected in the lung five days post infection [70]. Two studies in
healthy volunteers have been finished (NCT02558413,
NCT02668367), but thus far no results have been made public.
Recruitment to test safety, efficacy as well as pharmacokinetics
in a RSV viral challenge study is currently ongoing (NCT02718937).
4.1.2.1.7. P13 and C15. The benzenesulfonamide-based compound
P13 and the diazepane-based compound C15 were reported to
inhibit RSV-A strain A2 replication with EC50 values of 0.11 lm
(P13) and 0.13 lM (C15) [71]. Drug-resistant variants were
selected for both P13 and C15 and were shown to carry amino acid
substitutions in the F protein, more specifically D489G (for C15
resistant strain), T400I and N197T (for P13-selected virus variants).
These three mutations are located in the HR1-region (N197T), HR-2
region (D489G) and in the cysteine-rich domain of the F1 subunit
region (T400I) (Fig. 2A). These are regions where resistance associ-
ated mutations to the compounds BMS-433771, VP-14637 and
TMC353121 have also been detected, indicating a similar (perhaps
not identical) mode of action for these compounds.4.1.2.2. JNJ-53718678. JNJ-53718678 (Johnson & Johnson) is an RSV
inhibitor in clinical development. No data have been reported thus
far on the biological, structural or other characteristics of this com-
pound. Its safety, tolerability and pharmacokinetic profile in
healthy Japanese adults were investigated (NCT02398591) as well
as different oral liquid formulations (NCT02426632). In a phase 2al systems in respiratory syncytial virus antiviral drug discovery, Biochem.
6 E. Heylen et al. / Biochemical Pharmacology xxx (2016) xxx–xxxrandomized, double-blinded, placebo-controlled study the antivi-
ral activity, safety, and pharmacokinetics of repeated doses of
orally administered JNJ-53718678 were studied against RSV infec-
tions in healthy adults who had been challenged with RSV. This
study was completed in September 2015 (NCT02387606). Cur-
rently a study in infants hospitalized because of an RSV infection,
is planned (NCT02593851). Participants are also being recruited
to a study to assess the effects of Itraconazole and Rifampicin on
the single-dose pharmacokinetics of JNJ-53718678 in healthy
adults (NCT02729467).
4.1.2.3. AK-0529. AK-0529 (Ark Biosciences) is an RSV inhibitor for
which no structure nor results have been published to date. In a
randomized, double-blinded, placebo-controlled phase 1 study of
orally administered AK-0529, safety, tolerability, and pharmacoki-
netics of single ascending doses and multiple ascending doses were
evaluated. The compound was well tolerated, with an excellent
safety profile [72]. At the moment two other clinical studies have
been registered to be carried out in Australia (NCT02460016 and
NCT02654171). The first trial is a Phase 1b study in which also
the potential anti-viral effect of single dose of AK0529 will be stud-
ied in infants hospitalized with an RSV infection, the second trial is
a phase 2 study.
4.1.2.4. RFI-641. RFI-641 (Pfizer) is a small dendrimer-like com-
pound with potent in vitro activity against both RSV-A and RSV-B
laboratory strains and clinical isolates (EC50 values around
20 nM) [73]. The compound was shown to inhibit binding as well
as fusion of RSV with cells and showed to be resistant to viruses
showing a mutation at position 446 of the F-protein (Fig. 2A)
[74,75]. This bi-phenyl analog of CL-309623 is also potent in differ-
ent animal models when delivered intranasally [76,77]. More
specifically, 1.3 mg/kg administered 2 h prior to virus challenge
of mice reduced virus lung titers by 1.5 log10. In cotton rats a dose
of 10 mg/kg reduced the lung viral titer by 2.6–3.2 log10 when
given at a same prophylactic dosing regimen. In African Green
Monkeys infected with RSV, RFI-641 when given by inhalation
using a nebulizer reservoir at a dose of 15 mg/ml 2 h prior to infec-
tion caused a 3.4 log10 reduction in viral load (In bronchial lavage
7 days post infection). At a 6 mg dose, viral titers were significantly
lower on days 4–9 (peak viral load) with a 1.8–3.4 log10 reduction.
In addition to being active when given prophylactically, the com-
pound was also shown to be active therapeutically in the monkey
model (when the first dose given 24 h after infection in the monkey
model and continued once per day for 8 days) [76].
4.2. Non-entry as target (Fig. 3)
4.2.1. L-protein inhibitors
All negative-strand RNA viruses encode a L (‘‘large”) protein
that has several biochemical activities. This protein functions as
the RNA-dependent RNA polymerase that replicates the viral gen-
ome and transcribes mRNAs. The L-protein is also a capping
enzyme that guanylylates and methylates the 50 end of the viral
mRNA transcripts. Moreover it has poly-adenylation activity aimed
at protecting the 30-ends of the viral mRNAs (for a recent summary
[78]). Viral polymerases remain the leading therapeutic targets for
treating viral infections. Different polymerase inhibitors have been
approved for infections with herpes, hepatitis B, hepatitis C viruses
as well as HIV and have been crucial in improving the quality of life
of these patients.
4.2.1.1. Ribavirin. Ribavirin is the only licensed drug for the treat-
ment of RSV. Because of toxicity (including bone marrow suppres-
sion and potential carcinogenicity and teratogenicity) and
marginal efficacy it is not routinely used in infants hospitalizedPlease cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.014with RSV infection. In addition it is difficult to administer (aerosol)
and carries a high cost [79].
Several mechanisms of action for the antiviral activity of rib-
avirin have been purposed including inhibition of the cellular
enzyme inosine 5-monophosphate dehydrogenase (IMPDH),
immunomodulation of antiviral innate and cellular responses,
chain termination during viral RNA synthesis, inhibition of viral
mRNA capping and accumulation of mutations in viral genomes
[80]. These have been discussed extensively elsewhere and will
not be addressed here.
4.2.1.2. ALS-008176: Inhibition of RSV polymerase by a nucleoside
analog chain terminator. ALS-008176, a prodrug of the novel RSV
replication inhibitor ALS-008112 (Alios Janssen), is a cytidine
nucleoside analog. Upon oral administration ALS-008176 is metab-
olized in the plasma to ALS-008112, which is taken up by different
cell types including those of the respiratory track. Intracellular
ALS-008112 is further metabolized by cellular enzymes to the
active metabolite ALS-008112-50-triphosphate which is the active
inhibitor of the RSV polymerase. In vivo studies showed that this
active metabolite has a long intracellular half-life (29 h) in the
lung of monkeys. Similarly, biochemical studies revealed that it
is a potent and selective inhibitor of RSV RNA-dependent RNA
polymerase activity (Ki of 0.09 lM), via a classic chain termination
mechanism. Two independent in vitro experiments identified resis-
tant virus population in which 4 mutations (M628L, A789V, L795I
and I796V) in the L-protein were found together on the large
majority of the genomes sequenced (Fig. 2B). The last three of
these mutations are in close proximity to the catalytic motif
C (810GDNQ813) that is responsible for nucleotide incorporation
by paramyxovirus RNA polymerases. In vitro experiments also
show that ALS-008112 is a broad-spectrum inhibitor of paramyx-
oviruses as it shows significant activity on parainfluenza virus
and even vesicular stomatitis virus (Rhabdovirus family). This is
in accordance with the conservation of the active site catalytic
motif C of these RNA polymerases. No activity was detected on
negative strand RNA viruses beyond the paramyxo- and
rhabdovirus families, nor was activity noted against any of the
tested positive strand RNA viruses [81].
ALS-008176 is currently being actively evaluated in clinical tri-
als. The results of a first human challenge study have been reported
[82]. In this study healthy adult volunteers were challenged with 4
log10 PFU of the RSV-A Memphis 37b challenge virus. Participants
were monitored twice daily for RSV infection by RT-PCR assay on
nasal washings and upon qualitative detection of RSV or on the
morning of day 6, whichever occurred first, participants were ran-
domized and received ALS-008176 or placebo. Three ALS-008176
dosing regimens were evaluated over the three study periods: a
single loading dose of 750 mg followed by 9 maintenance doses
of 500 mg, a single loading dose of 750 mg followed by 9 mainte-
nance doses of 150 mg and 10 doses of 375 mg. These doses were
administrated every 12 h over a period of 5 days and RSV load in
nasal-wash samples was measured twice daily until day 12 and
once on study days 16 and 28. In this study ALS-008176 treatment
was not associated with any serious adverse events or premature
discontinuation of the study in any of the participants. Absolute
reductions in viral load in the treated group was apparent within
12 h after start of treatment and the mean time to non-
detectability for RSV RNA ranged from 1.3 to 2.3 days (compare
with 7.2 days for the placebo group). The clearance rate of RSV
RNA (the slope of the viral load) was most rapid in the two regi-
mens that incorporated a loading dose and the clearance rates
for all three regimens were significantly more rapid during the first
48 h than the rates for placebo. In addition, the severity of RSV dis-
ease, as assessed by means of symptom scores and quantity of
nasal mucus production, was significantly lower in the threel systems in respiratory syncytial virus antiviral drug discovery, Biochem.
Fig. 3. Structural formulae of molecules inhibiting the respiratory syncytial virus targeting different viral proteins (shown in boxes).
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of the resistance associated mutations found in vitro could be
detected in any of the samples from this in vivo study. In conclu-
sion this challenge experiment shows that a nucleoside inhibitor
can have a significant beneficial effect on RSV infections in humans
in an experimental setting. However, this study design is signifi-
cantly different from a clinical setting where the patients are small
children with no or less preexisting immunity presenting with sev-
ere symptoms. For this purpose, clinical trials in infants hospital-
ized with RSV infection are currently ongoing (NCT02202356).
4.2.1.3. BI-D inhibits the viral mRNA guanylylation activity of the
L-protein. BI-D (Boehringer Ingelheim) is a molecule that inhibits
the in vitro replication of RSV-A and RSV-B in the submicromolar
range and a selectivity index of 400 [83]. Other groups have
reported a significantly lower selectivity (30x) [84]. The com-
pound was originally identified as a RSV polymerase inhibitor by
screening compounds in a biochemical assay [85]. Further analysisPlease cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.014revealed that the molecule does not inhibit the initiation or elonga-
tion of viral RNA transcription but that it causes premature abor-
tion of transcription leading to increased amounts of short RNA
species (<50 nt). Strains, selected to be resistance against BI-D,
were shown to carry mutations at positions 1269, 1381 and 1421
of the L-protein (Fig. 2B) and a sequence motif around position
1269 indicated this is the location of a nucleotide binding pocket
essential for RNA capping. Together with the appearance of short
RNAs in infected cells this led the investigators to hypothesize that
BI-D prevents co-transcriptional capping of viral mRNA’s and pre-
mature abortion of transcription. A similar interplay between 50
capping and transcription elongation had already been proposed
for the vesicular stomatitis virus. Subsequent biochemical work
revealed that the viral mRNA transcripts formed in the presence
of BI-D indeed have a 50 pppGp moiety whereas in the absence of
inhibitor this is a fully capped 50 end moiety (7mGpppG(m)p) (83).
More recent analysis of the positions of the above resistance asso-
ciated mutations in the context of the VSV L protein structurel systems in respiratory syncytial virus antiviral drug discovery, Biochem.
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sible for GDP-polyribonucleotidyltransferase (PRNTase) activity
[86,87]. This PRNTase activity is responsible for the capping of
the viral mRNA’s. The 3D structure of the VSV-L protein also pro-
vides hints as to how capping and mRNA elongation could be
linked. During early transcription the PRNTase active site of the
capping domain is directed toward the polymerase active site.
When the transcript reaches a certain length its 50 end reaches
the capping domain and the PRNTase activity adds the cap to the
viral mRNA. Only then the capping domain is displaced releasing
the 50end of the viral mRNA allowing further elongation of the viral
mRNA and further methylation of the cap. If the capping reaction is
inhibited and the capping domain is not displaced then the short
mRNA cannot be elongated further and only short uncapped viral
mRNA’s can be produced [87].
In vivo efficacy studies in RSV-infected mice showed that com-
pound D reduced the infectious viral load in mice lung by 0.6 log
upon intranasal administration at 0.4 mg/kg/day [83]. To our
knowledge, clinical trials have not been initiated. As the capping
of viral mRNA is a unique biochemical mechanism, which is clearly
distinct from the host cell capping machinery, this process remains
a promising target for antiviral drug discovery [78].
4.2.1.4. AZ-27: A non-nucleoside L-protein inhibitor. AZ-27 (Astra
Zeneca) is a follow-up of YM-53403, which was discovered in a
CPE-based screening effort, that inhibits RSV-A replication (both
lab strains and clinical isolates) with EC50 values in the 10–
40 nM range. The activity against RSV-B is much less pronounced
(EC50  1 lM). The molecule retains in vitro activity when added
after viral entry and is as well effective in a replicon assay, which
indicates an inhibition of the intracellular replication phase of
the virus. In all independently selected drug-resistant variants
mutation Y1631H was identified in the L-gene (Fig. 2B). The inhibi-
tor is not cross-resistant with BI-D, ribavirin or RSV604 (see infra).
Based upon an alignment of the RSV and VSV L-protein, Y1631 is
located in a linker region between the connector domain, which
connects the capping domain and the methyltransferase domain
[87]. The nearby amino acid sequences are 100% conserved in the
L protein across RSV A and B isolates, while differing from those
observed in other paramyxoviruses analyzed. Subsequent investi-
gations have shown that AZ-27 differentially inhibits the different
RSV polymerase activities [88], i.e. AZ-27 has a more potent inhibi-
tory effect on the synthesis of transcripts from genes at the 30 end
of the genome than on those from the 50 end, and this follows the
same pattern of activity observed on RSV A and B as in the cell
based assay. More in detail the compound inhibits the initiation
of de novo RNA synthesis at the promoter, which prevents both
transcription and RNA replication. Analysis of small RNA products
shows inhibition of the formation of even the first phosphodiester
bond in RNA synthesis. It is hypothesized that AZ-27 impairs the
ability of the RSV RNA-dependent RNA polymerase (RdRp) to adopt
a particular structural form required for initiation of RNA synthesis
[88]. Position Y1631 is in this model seen as part of a hinge region
important for RdRp flexibility and dynamic transitions between a
state of initiation and elongation of RNA synthesis. There are so
far no studies reported that investigated whether AZ-27 affects
the PRNTase and/or MTase functions of the RdRp.
4.2.2. N-protein targeting RSV inhibitor
The viral nucleoprotein N tightly binds the RSV genomic RNA to
form a left-handed helical N-RNA ribonucleoprotein complex
(RNP). This RNP is the template for transcription and replication
by the RdRp (L protein). Viral RNA synthesis is mediated by the
viral Phospho- (P) protein which is a multifunctional protein that
interacts with L and N. It allows efficient and specific recognition
of the RNP template by the RdRp and subsequent RNA polymeriza-Please cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.014tion. In this way P permits the continued contact between the RdRp
and the RNP as the RdRp progresses. The detailed dynamics of N, P,
L and viral RNA interactions during viral RNA synthesis are not
fully understood but different observations points toward the fol-
lowing model. The N protein consists of a N- and C-terminal
domain (NTD, CTD) linked with a hinge region. Intermolecular
interactions between the different N proteins and the viral RNA,
located in the hinge region between the CTD and NTD, are suffi-
cient to form the helical RNP complex. The P protein is multimeric
and interacts with its C-terminal peptide in a hydrophobic pocket
in the N-NTD. This causes the N-protein hinge region to open up
and allow access of the L protein to the viral RNA. As the P protein
is multimeric the complex will interact with more N-proteins at
the same time and in that way release the RNA template along
multiple sequential N-proteins. As the L-protein translocates
during RNA synthesis existing N-P interactions will continuously
disappear while new ones are formed. In this way the viral poly-
merase complex can crawl further along its template. In addition
to viral proteins several host factors have been proposed to be
involved in this complex mechanism of viral RNA synthesis [89].
4.2.2.1. RSV604: An N-protein inhibitor. RSV604 (Astra Zeneca) is a
small molecule inhibitor of RSV A and B replication with EC50
0.8 lM against both viruses. The compound has been obtained
through optimization of a hit identified in a CPE-based screenings
effort. The compound inhibits viral replication at a post-entry stage
of the replication cycle. Drug-resistant variants (>10-fold loss in
antiviral activity) selected in vitro carry mutations I129L and
L139I in the N-protein [90].
RSV604 inhibits both viral RNA synthesis and the infectivity of
released virus. Inhibition of RNA synthesis is cell-line dependent,
as shown in infected cells and viral replicons (i.e. the effect is
observed in HeLa but not in BHK cells). Using surface plasmon res-
onance it was demonstrated that the N protein is indeed the target
of the molecule. The cell-type dependent antiviral activity may
suggest that also host factors are involved in the mechanism of
actions. This may also be in line with the location of the RSV604
associated resistance mutations, which is on the surface of the
N-protein and thus exposed [91].
In a Phase I study orally administered RSV604 was shown to be
safe and well tolerated in healthy volunteers. A loading dose of
600 mg and subsequent dosing at 450 mg/day resulted in a trough
(Cmin) concentrations above the EC90 throughout the study [92]. A
proof-of-concept trial was then organized in hematopoietic stem
cell transplant patients, where RSV infections are an important
health risk. However this trial seemed to have been very challeng-
ing for several reasons such as the limited number of patients, their
complex underlying conditions and the seasonality of the virus.
During the trial most patients had lower RSV604 drug levels than
anticipated and no significant difference in viral load with placebo
could be observed. Only in patients with RSV604 plasma levels
above the EC90 a drop in viral load was reached [93].
4.2.3. Targeting the N-P protein-protein interaction
Recently the X-ray structures of the N-NTD in complex with C-
terminal peptides of P-protein were solved [94]. This gained
detailed insight into the N-NTD:P-CTD interaction and how the ter-
minal residues of the P protein penetrate deeply into a pocket in
the N-protein. As this N-P interaction is crucial for viral RNA syn-
thesis this pocket was considered a promising target for interfering
with virus replication. An in silico screening campaign and subse-
quent structural studies identified a chemical series of compounds
with a 1-benzyl-1H-pyrazole-3,5-dicarboxylate (BPdC) scaffold
that bind this pocket P-CTD. Experiments using surface plasmon
resonance demonstrated competition between the C-terminal pep-
tide of P and the BPdC molecules. Preliminary cell-based antivirall systems in respiratory syncytial virus antiviral drug discovery, Biochem.
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show significant inhibitory activity. This was not a surprise as
the molecule has two negatively charged carboxylates that most
likely prevent cellular uptake. A prodrug was made in which the
carboxylates were shielded by a pH sensitive moiety that is
released by hydrolysis in the cytosol. This prodrug showed some
antiviral activity but with a very limited selectivity index
(EC50  122 lM, SI  2). With this very limited selectivity it will
be very challenging to prove that the activity observed in cell cul-
ture is indeed linked to the proposed mechanism of action. No
activity could be detected on the in vitro replication of VSV demon-
strating the specificity of the approach. Note that in the family of
rhabdoviruses (like VSV) it is the N-terminal region of P that binds
N [89].
4.2.4. Targeting the SH-protein
Together with the F and G protein, the SH protein (small-
hydrophobic protein) is one of the tree envelop proteins of RSV.
While F and G are clearly involved in entry in the host cell the role
of SH is less clear. The SH protein is a viroporin, a family of small
hydrophobic proteins encoded by several animal viruses that, upon
oligomerization, form hydrophilic pore in the virus infected cell.
They seemed to have a wide variety of functions in the viral life
cycle, often associated with immunomodulatory activity.
A role of SH in RSV pathogenesis was suspected early as strains
lacking SH behave similar to the wild-type in cell culture (replica-
tion kinetics, plague formation. . .) but showed severe attenuation
upon infection of chimpanzee [95]. In mice these strains replicate
to the same extent as WT RSV in the lungs but significantly less
in the upper respiratory track [96]. This attenuation could be due
to an increased IL-1b response to RSVDSH in vivo leading to the
hypothesis that the pore structure of the SH protein counteracts
the activation of the NLRP3 inflammasome by ionic changes [97].
Because of this attenuation deleting the SH gene is being
explored for vaccine approaches. In addition targeting the SH pro-
tein may open up novel antiviral therapies. Recently pyronin B was
identified as an inhibitor of the pore function of SH in a biochem-
ical screening assay. Detailed biophysical characterization indi-
cated that the molecule binds SH at the lipid-facing side of the
TMa-helices and not into the pore lumen. This indicates an allos-
teric mechanism of inhibition similar to other viroporin inhibitors
(rimantadine, the influenza M2 inhibitor). Interestingly the pro-
posed binding site for pyronin B on SH is highly conserved in
human RSV strains. Cell-based experiment demonstrated an
antiviral activity of the molecule (EC50 100 nM) although cellular
toxicity or any other potential effect of the molecule on the host
cell was not addressed in this study [98].
4.2.5. Targeting the M2-1 protein
The RSV M2-1 protein (194 amino acids) is a homotetrameric
transcription processivity factor that binds in a competitive man-
ner to RNA and the P protein via its core domain. It prevents pre-
mature termination of transcription both intra- and inter-
genetically, making the M2-1 protein essential for the efficient pro-
cessing of viral RNA during the viral lifecycle [99–103]. In vitro
experiments have shown that M2-1 binds preferentially to
positive-sense viral gene end and poly-A sequences [100,104]
however, the exact mechanisms by which M2-1 improves tran-
scription efficiency is not fully understood.
In a recent study it was reported that cyclopamine (CPM) is as a
potent inhibitor of RSV infection both in vitro as in vivo [105]. CMP
is well characterized as an antagonist of the smoothened protein
(Smo), playing a role in embryonic development, cell differentia-
tion and tumorigenesis [106,107]. However, the inhibition of RSV
is mediated through specific inhibition of M2-1-mediated RSV
transcription and acts independently of the Smo receptor. APlease cite this article in press as: E. Heylen et al., Drug candidates and mode
Pharmacol. (2016), http://dx.doi.org/10.1016/j.bcp.2016.09.014resistance mutation was found in three independently generated
CPM-resistant RSV strains at position 151 (R151K), which is
located in a region previously described for its role in RNA and P
binding [100,101].
5. Targeting host factors
As the human genome is much more stable than that of viruses,
targeting an essential host factor in the viral replication cycle has
been proposed as an alternative strategy to develop prophylaxis
or therapy for RSV infections. A major challenge of such approach
is to avoid undesired off-target effects or other toxicity.
Potential host factor targets for treatment or prophylaxis include
some of the tentative RSV receptors, co-receptors or co-factors,
such as the fractalkine receptor CX3CR1 [108,109], glycoproteins/
heparin [110], intercellular adhesion molecule (ICAM-1) [111],
annexin II [112], toll-like receptor 4 [113], Akt [114], and nucleolin.
Substantial efforts have been made in exploring the potential of the
latter as a target for inhibition of RSV replication. It is an essential
protein found in all cells, which has been identified by different
techniques (including a virus overlay protein binding assay, mass
spectrometry and immunoprecipitation) as a potential cellular
receptor for RSV [115]. Based on antibody binding epitopes studies,
a potential RSV-F protein-nucleolin interaction site may occur
around amino acids 429–437 (antigenic site IV), which is located
in the apex of the F protein [116–118]. An RSV receptor antagonist,
AS-1411, is a guanine-rich oligonucleotide that was originally
developed for cancer treatment and targets nucleolin on cell sur-
faces [119]. The ability to inhibit RSV in vivo has been demonstrated
in mice, which showed that AS-1411 given intranasally (50 mg/kg)
4 h prior to RSV challenge reduced the lung levels of the virus by
50% on day 4 post infection [120].
6. Final remarks
RSV remains an important pathogen in young children as well
as in the elderly. No vaccines or antivirals are available to prevent
or treat RSV infection Here we reviewed the progress made on sev-
eral chemical series that inhibit RSV replication with a wide variety
of molecular mechanisms of action. Many of the RSV proteins have
now been studied functionally and structurally, some in the pres-
ence of small-molecule inhibitors. Recently convincing efficacy of
both a fusion and polymerase inhibitor have been demonstrated
in phase 2a clinical studies (in healthy volunteers challenged with
the virus). These studies are also paving the way for the develop-
ment of yet other RSV inhibitors. We are now at a turning point
in RSV antiviral drug discovery as the first phase 2 trials with novel
small molecules in small children are being performed. This brings
hope that the first generation anti-RSV drugs for this patient pop-
ulation may get approved within the next few years. A continued
effort is needed to ensure the successful development of a second
generation of RSV inhibitors, ideally with a different resistance
profile.
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